18F-FMISO for Anoxia

Phase-Based Progress Estimates
Memorial Sloan Kettering Cancer Center, New York, NY
Anoxia+3 More
18F-FMISO - Drug
All Sexes
What conditions do you have?

Study Summary

This study is evaluating whether a new imaging agent called 18F-FMISO can predict if patients with lung cancer will respond to standard therapy, as well as whether disease will reoccur in the future. The study will also investigate whether a 18F-FDG PET scan in the middle of radiation

See full description

Eligible Conditions

  • Anoxia
  • Non-Small Cell Lung Carcinoma (NSCLC)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether 18F-FMISO will improve 2 primary outcomes and 1 secondary outcome in patients with Anoxia. Measurement will happen over the course of 2 years.

2 years
prognostic value of fluorine-18-labeled fluoro-misonidazole (18F-FMISO)
3 years
overall survival
progression-free survival (PFS)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

This trial requires 29 total participants across 1 different treatment group

This trial involves a single treatment. 18F-FMISO is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

18F-FMISO PET/CTAll enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 3 years for reporting.

Closest Location

Memorial Sloan Kettering Cancer Center - New York, NY

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 8 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Pathologic confirmation of NSCLC at MSKCC
No prior treatment for this diagnosis of NSCLC
Patient to be treated with neoadjuvant chemotherapy (35 patients total) or patient to be treated with definitive RT,sequential chemo-RT, or concurrent chemo-RT (minimum dose of 50 Gy in 25 fractions) (25 patients total)
Tumor must measure ≥ 2cm on CT
Age ≥ 18 years
Ability to hold the breath for 10 seconds.
Karnofsky performance status ≥ 70%
Women of childbearing age must have a negative blood pregnancy test

Patient Q&A Section

What are common treatments for carcinoma, non-small-cell lung?

"Commonly, patients with carcinoma, non-small-cell lung receive chemotherapy, endoscopic image-guided ablation, thoracic radiotherapy, surgery (whole thorax pneumonectomy or lobectomy), or chemotherapy in combination. Other common therapies include endoscopic image-guided ablation, embolisation, percutaneous ethanol injection therapy, radiosurgery, cryosurgery, and chemotherapy." - Anonymous Online Contributor

Unverified Answer

What causes carcinoma, non-small-cell lung?

"If the carcinoma is not caused by smoking, other causes may be present. These include the other carcinoma susceptibility genes. Although the presence of specific cancer risk factors has not been demonstrated as in colorectal, bladder and pancreas cancer, there is also considerable interest in studies of the effect of genetic risk factors on prostate cancer risk." - Anonymous Online Contributor

Unverified Answer

What is carcinoma, non-small-cell lung?

"There are many types of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer), some of which are different depending on which lobe of the lung is involved. They include the lower, middle, and upper lung; and some small cell, bronchial, and small cell lung cancer types. Symptoms include shortness of breath, especially when lying flat, unexplained weight loss or unintentional weight loss, and coughing up blood or blood-stained sputum. Lung cancer has the largest overall 5-year survival rate of all cancers worldwide and the highest survival rate in people who smoke tobacco. If the disease is detected early, lung cancer can be treated and many people diagnosed early have a chance of recovery." - Anonymous Online Contributor

Unverified Answer

What are the signs of carcinoma, non-small-cell lung?

"The signs of carinoma, non-small-cell lung are generally related to tissue effects rather than specific changes in the lungs on an underlying level. Specific signs involve lung infiltrates on chest X-ray and may be more common in an advanced stage of the disease." - Anonymous Online Contributor

Unverified Answer

How many people get carcinoma, non-small-cell lung a year in the United States?

"around 4 million Americans are afflicted with [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer), with the number expected to increase in the U.S. to more than 22 million by 2015 when there will be an additional 9,900 new cases of lung cancer. Lung cancer is a common form of cancer in the United States." - Anonymous Online Contributor

Unverified Answer

Can carcinoma, non-small-cell lung be cured?

"Based on our patient population, it is difficult to state that either lung cancer surgery or adjuvant therapies can cure NSCLC. Further studies based on prospective cohorts and randomized trials evaluating adjuvant therapies or specific surgery protocols are needed to conclude that lung cancer can be cured." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of pet/ct?

"This is a common concern among patients being considered for PET/CT and/or PET/MRI, and can be addressed in a variety of ways. Care should be taken at all times during PET/CT imaging to avoid potential injuries to the patient from moving equipment, the radioactive material, or the scanner itself. There is evidence that PET/MRI can also cause similar side effects with higher risks of injury. The impact of most side effects on quality of life is unknown, although given the magnitude and burden of side effects, efforts to reduce side effects should be pursued no matter the imaging modality." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating carcinoma, non-small-cell lung?

"There may be additional potential for targeting EGFR-TKIs instead of non-tyrosine kinase targeting agents for carcinoma, non-small-cell lung cancer. A possible future development is to use EGFR-TKI combined with a Bcl-2 inhibitor to reduce the resistance of carcinoma, non-small-cell lung cancer." - Anonymous Online Contributor

Unverified Answer

Does carcinoma, non-small-cell lung run in families?

"Results from a recent paper have provided some evidence to support the hypothesis that certain genes with an important role in [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer)s are inherited from a common ancestor. However, a significant environmental component must remain so that all cancers in relatives is a true indicator of genetic liability." - Anonymous Online Contributor

Unverified Answer

What does pet/ct usually treat?

"In a retrospective case series, a significant percentage of animals treated with CT scan for Feline non-small-cell lung cancer had concurrent skin cancers in the same location, as did a smaller percentage of Feline Follicular cell sarcomas. It is necessary to inform patients with this concurrent skin cancers that they are at risk for developing these secondary tumors." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of carcinoma, non-small-cell lung?

"The two most important factors influencing NSCLC risk are lifestyle factors and environmental exposures. Smoking cessation or cessation of passive exposure to tobacco-related carcinogens had a strong association with NSCLC, especially adenocarcinoma. The effects of passive exposure to passive smoke in general were not clarified due to the complexity of the study design." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for carcinoma, non-small-cell lung?

"Although we were not able to verify the effect of therapy on survival, we found that several patients with a good overall survival benefited from the clinical trials of carcinoma, non-small-cell lung." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Anoxia by sharing your contact details with the study coordinator.